A study testing the safety and efficacy of using dasatinib or imatinib along with chemotherapy with blinatumomab in patients with acute lymphoblastic leukemia (ALL)
Full IRB Study Title:
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
IRB Study ID: 2025-204
Please view all study details on clinicaltrials.gov
Study Sponsor:
Children's Oncology Group
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Kelly Culp
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
